Role of proteasomes in disease

被引:164
作者
Dahlmann, Burkhardt [1 ]
机构
[1] Charite, Inst Biochem, D-10117 Berlin, Germany
来源
BMC BIOCHEMISTRY | 2007年 / 8卷
关键词
D O I
10.1186/1471-2091-8-S1-S3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A functional ubiquitin proteasome system is essential for all eukaryotic cells and therefore any alteration to its components has potential pathological consequences. Though the exact underlying mechanism is unclear, an age-related decrease in proteasome activity weakens cellular capacity to remove oxidatively modified proteins and favours the development of neurodegenerative and cardiac diseases. Up-regulation of proteasome activity is characteristic of muscle wasting conditions including sepsis, cachexia and uraemia, but may not be rate limiting. Meanwhile, enhanced presence of immunoproteasomes in aging brain and muscle tissue could reflect a persistent inflammatory defence and anti-stress mechanism, whereas in cancer cells, their down-regulation reflects a means by which to escape immune surveillance. Hence, induction of apoptosis by synthetic proteasome inhibitors is a potential treatment strategy for cancer, whereas for other diseases such as neurodegeneration, the use of proteasome-activating or -modulating compounds could be more effective.
引用
收藏
页数:12
相关论文
共 184 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   Novel inhibitors of the proteasome and their therapeutic use in inflammation [J].
Adams, J ;
Stein, R .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 31, 1996, 31 :279-288
[3]   Ubiquitin: not just for proteasomes anymore [J].
Aguilar, RC ;
Wendland, B .
CURRENT OPINION IN CELL BIOLOGY, 2003, 15 (02) :184-190
[4]   20S proteasomal degradation of ornithine decarboxylase is regulated by NQ01 [J].
Asher, G ;
Bercovich, Z ;
Tsvetkov, P ;
Shaul, Y ;
Kahana, C .
MOLECULAR CELL, 2005, 17 (05) :645-655
[5]   The ubiquitin-proteasome system and skeletal muscle wasting [J].
Attaix, D ;
Ventadour, S ;
Codran, A ;
Béchet, D ;
Taillandier, D ;
Combaret, L .
ESSAYS IN BIOCHEMISTRY, VOL 41: THE UBIQUITIN-PROTEASOME SYSTEM, 2005, 41 :173-186
[6]   PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation [J].
Bao, JL ;
Sato, K ;
Li, M ;
Gao, YH ;
Abid, R ;
Aird, W ;
Simons, M ;
Post, MJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (06) :H2612-H2618
[7]   Changes in 20S proteasome activity during ageing of the LOU rat [J].
Bardag-Gorce, F ;
Farout, L ;
Veyrat-Durebex, C ;
Briand, Y ;
Briand, M .
MOLECULAR BIOLOGY REPORTS, 1999, 26 (1-2) :89-93
[8]   Impairment of the ubiquitin-proteasome system by protein aggregation [J].
Bence, NF ;
Sampat, RM ;
Kopito, RR .
SCIENCE, 2001, 292 (5521) :1552-1555
[9]   Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors [J].
Bogyo, M ;
McMaster, JS ;
Gaczynska, M ;
Tortorella, D ;
Goldberg, AL ;
Ploegh, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6629-6634
[10]   Phosphorylation of 20S proteasome alpha subunit C8 (α7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by γ-interferon [J].
Bose, S ;
Stratford, FLL ;
Broadfoot, KI ;
Mason, GGF ;
Rivett, AJ .
BIOCHEMICAL JOURNAL, 2004, 378 :177-184